Pharmacology and Analytical Facility - HPLC and Mass Spectrometry Facility This facility provides access to sophisticated HPLC, ultra high performance liquid chromatographic and mass spectrometry instruments. In this facility, analytical assay methodologies can be developed and validated using UPLC/HPLC equipment with a broad array of quantitative detection systems (e.g. UV, photodiode array, fluorescence, radiometric, light scattering, electrochemical). Current mass spectrometry instruments include a simple single quad LC/MS instrument for use in molecular weight determinations as well as more complex tandem mass spectrometers (7 total), including a time-of-flight instrument for more intricate drug metabolism studies and experiments requiring accurate mass weight measurements. In addition, a GC/MS instrument is available for separation and quantitation of volatile compounds. Recently added were automated solid phase and liquid extraction platforms capable of isolating multiple analytes of interest (drugs, macromolecules, and protein drug targets) from complex biomatrices (blood, plasma, normal organ tissues, and tumors). These extraction systems have improved both extraction efficiency and throughput in analytical sample preparation. The laboratory has supported experiments in chemical synthesis, drug library screening, medicinal chemistry, drug discovery and development, drug metabolism, drug target identification, drug metabolism, drug tissue biodistribution, systemic pharmacokinetics, drug production solubility and stability, formulation, and tumor biochemistry. The HPLC/Mass Spectrometry Facility sampled analysis increased over 340% since 1999 and is now analyzing more than 33,000 samples per year serving over 52 faculty members who are members of 21 CCSG Programs;90% of the users have peer-reviewed funding. The current source of funding is 48.4% CCSG, and 51.6% user fees. This state of the art facility is located at a newly renovated El Rio campus located approximately 1 mile from the main campus. This location is a 7250 sq. ft. facility that houses 4 faculty members and 21 support staff as well as 25 full UPLC/HPLC systems. In addition to the advanced analytical facility the combined program faculty have in excess of 60 years of experience in analytical chemistry, analytical method development and validation, isolation technologies, pharmacology, drug metabolism, and pharmacokinetic/pharmacodynamics. They act as an invaluable resource in experimental design, development and implementation to the user faculty who often lack the specific training to conduct experiments requiring quantitative analytical chemistry and pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310856
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$448,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chen, Han; Li, Chunyan; Peng, Xinxin et al. (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173:386-399.e12
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Huang, Shengjian; Jiang, Changying; Zhang, Hui et al. (2018) The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8:33
Hwang, Jessica P; Ahmed, Sairah; Ariza-Heredia, Ella J et al. (2018) Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 24:1094-1098
He, Jing; Huo, Lei; Ma, Junsheng et al. (2018) Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149:253-261
Schembre, Susan M; Liao, Yue; O'Connor, Sydney G et al. (2018) Mobile Ecological Momentary Diet Assessment Methods for Behavioral Research: Systematic Review. JMIR Mhealth Uhealth 6:e11170
Abbas, Hussein A; Bui, Ngoc Hoang Bao; Rajapakshe, Kimal et al. (2018) Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78:451-462
Zhu, Lele; Xie, Xiaoping; Zhang, Lingyun et al. (2018) TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun 9:2812
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177

Showing the most recent 10 out of 12418 publications